Company Genovis AB Nasdaq Stockholm
Equities
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
||
- SEK | - |
|
05-15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Enzyme
87.6
%
| 85 | 83.1 % | 139 | 87.6 % | +62.88% |
Antibodies
12.4
%
| 17 | 16.9 % | 20 | 12.4 % | +13.45% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Other Countries
99.5
%
| 102 | 99.4 % | 157 | 99.5 % | +54.72% |
Sweden
0.5
%
| 1 | 0.6 % | 1 | 0.5 % | +25.91% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
Susanne Ahlberg
IRC | Investor Relations Contact | 67 | 06-12-31 |
Rikke Rytter
SAM | Sales & Marketing | 57 | 20-12-31 |
Jonathan Sjögren
PRN | Corporate Officer/Principal | 39 | 13-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 20-05-04 | |
Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
Director/Board Member | 52 | 21-12-31 | |
Steve Jordan
BRD | Director/Board Member | 71 | 20-12-31 |
Company contact information
![address Genovis AB](https://cdn.zonebourse.com/static/address/12399233.png)
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-10.88% | 11.41B | |
-12.48% | 7.4B | |
+31.15% | 5.64B | |
-0.13% | 5.33B | |
-18.68% | 3.7B | |
+7.43% | 2.58B | |
-64.53% | 2.38B | |
+27.01% | 2.2B | |
-10.27% | 2.2B |
- Stock Market
- Equities
- GENO Stock
- Stock
- Company Genovis AB